Small bowel neuroendocrine tumors (SBNETs) have been increasing in frequency over the
past decades, and are now the most common type of small bowel tumor. Consequently …

These guidelines update previous guidance published in 2005. They have been revised by
a group who are members of the UK and Ireland Neuroendocrine Tumour Society with …

Previous ENETS guidelines [1, 8, 9] have discussed extensively the clinical symptomology,
diagnosis and treatment of localized, regionalized as well as distant Si-NENs. This fourth …

Therapeutic approaches for management of metastatic disease include surgical, medical,
radiological and nuclear medicine strategies. More recently, novel molecular targeted drugs …

Background: Somatostatin analogs have been shown to control the growth of well-
differentiated metastatic neuroendocrine tumors. Their effect on overall survival is a matter of …

Abstract Background Although neuroendocrine tumors (NETs) are rare, the number of
patients with NET is increasing. However, in Japan, there have been no epidemiological …

Neuroendocrine gastroenteropancreatic tumors (GEP-NETs) constitute a heterogeneous
group of tumors with their origin in neuroendocrine cells of the embryological gut. Most …

Since highly proliferative carcinomas with a neuroendocrine phenotype but poor histological
differentiation grade are extremely rare in the jejuno-ileum, management of such cases …

Abstract Background Neuroendocrine tumors (NETs) are a form of cancer that differ from
other neoplasia in that they synthesize, store, and secrete peptides, eg, chromogranin A …

In 1983, a monoclonal antibody, Ki67, was generated, that labeled the nuclei of proliferating
non-neoplastic and neoplastic cells. The name Ki67 derived from the city of Kiel (Ki) where …